Frontlight ResearchEarly access
CompletedNo phase
Optimizing Vancomycin Therapy in Children
Key facts
- Who runs it
- Children's Hospital of Philadelphia
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 29 people enrolled
- Started
- 12 Dec 2022
- Ended
- 22 Nov 2023
- Type of study
- Observational
- Record updated
- 20 December 2024
Who can take part
- Age
- 1 year to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Administered intravenous vancomycin via intermittent infusion,
- Eligible for vancomycin AUC monitoring, per the subject's clinical team, and
- Parental/guardian permission (informed consent)
Who cannot take part
- Receipt of renal replacement therapy, plasmapheresis, or extracorporeal membrane oxygenation (ECMO), or
- Unable to provide urine and blood samples
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
The purpose of Opt Vanc is to evaluate the feasibility of Bayesian dose adaptation, based on a previously-developed population pharmacokinetic (PK) model and a single optimally timed PK sample, to predict vancomycin area under the curve (AUC) in critically ill children.
The group in the trial
- Study Cohort
Recipients of vancomycin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 20 December 2024